Medicare AdvantagePrior AuthMedium impact
Bempedoic Acid Products (Revised)
Humana·Cardiology, Internal Medicine, Endocrinology +2 more·Medicare Advantage
Effective date
Apr 1, 2026
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage has revised its prior authorization policy for bempedoic acid products (Nexletol, Nexlizet) effective April 1, 2026. The policy maintains two coverage pathways: (1) hypercholesterolemia treatment after statin failure or statin intolerance, and (2) cardiovascular disease prevention in high-risk patients unable to tolerate statins. Prior authorization is required for both indications, with lipid level analysis required 8-12 weeks post-initiation.
Action Required
By April 1, 2026: Billing team must implement prior authorization requirements for all Nexletol (bempedoic acid) and Nexlizet (bempedoic acid/ezetimibe) claims submitted to Humana Medicare Advantage. Update billing software and EMR templates to: (1) Flag prescriptions for mandatory prior auth submission before claim processing; (2) Require documentation of hypercholesterolemia diagnosis or cardiovascular risk assessment; (3) Require evidence of statin therapy failure (LDL-C goals not met) OR documented statin intolerance (muscle symptoms, rhabdomyolysis); (4) Add clinical note requirement indicating lipid panel follow-up planned within 8-12 weeks. Front desk staff must alert providers during prescription entry. Verify current policy status at www.humana.com/PAL before submitting claims. Claims submitted without prior authorization will be denied. Providers should monitor for hyperuricemia and tendon rupture warnings per policy guidance.